We have recently shown that the targeting of HIF-1α with BAY87-2243 is effective in overcoming the intrinsic TP53-dependent and the SC-induced fludarabine resistance of CLL cells [8]. The gene discussed is HIF1A; the disease is B-cell chronic lymphocytic leukemia.